EG13691A - Process for preparing hydration therapeutic agents - Google Patents

Process for preparing hydration therapeutic agents

Info

Publication number
EG13691A
EG13691A EG320/78A EG32078A EG13691A EG 13691 A EG13691 A EG 13691A EG 320/78 A EG320/78 A EG 320/78A EG 32078 A EG32078 A EG 32078A EG 13691 A EG13691 A EG 13691A
Authority
EG
Egypt
Prior art keywords
therapeutic agents
hydration
preparing
preparing hydration
therapeutic
Prior art date
Application number
EG320/78A
Other languages
English (en)
Inventor
Reinhard Sarges
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG13691A publication Critical patent/EG13691A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EG320/78A 1977-05-23 1978-05-20 Process for preparing hydration therapeutic agents EG13691A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/799,586 US4130714A (en) 1977-05-23 1977-05-23 Hydantoin therapeutic agents

Publications (1)

Publication Number Publication Date
EG13691A true EG13691A (en) 1982-12-31

Family

ID=25176274

Family Applications (1)

Application Number Title Priority Date Filing Date
EG320/78A EG13691A (en) 1977-05-23 1978-05-20 Process for preparing hydration therapeutic agents

Country Status (37)

Country Link
US (1) US4130714A (fr)
JP (1) JPS6035350B2 (fr)
AR (1) AR219531A1 (fr)
AT (1) AT357170B (fr)
AU (1) AU499518B1 (fr)
BE (1) BE867248A (fr)
CA (1) CA1088073A (fr)
CH (1) CH631455A5 (fr)
CS (1) CS200550B2 (fr)
DD (1) DD137107A5 (fr)
DE (2) DE2821966C2 (fr)
DK (1) DK147941C (fr)
EG (1) EG13691A (fr)
ES (1) ES470070A1 (fr)
FI (1) FI62838C (fr)
FR (1) FR2392024A1 (fr)
GB (1) GB1572688A (fr)
GR (1) GR68694B (fr)
HK (1) HK53981A (fr)
HU (1) HU177718B (fr)
IE (1) IE47273B1 (fr)
IL (1) IL54754A (fr)
IN (1) IN147854B (fr)
IT (1) IT1096306B (fr)
KE (1) KE3168A (fr)
LU (1) LU79685A1 (fr)
MY (1) MY8200156A (fr)
NL (1) NL7804158A (fr)
NO (1) NO150206C (fr)
NZ (1) NZ187334A (fr)
PH (1) PH13828A (fr)
PL (1) PL110460B1 (fr)
PT (1) PT68071B (fr)
SE (1) SE437375B (fr)
SU (1) SU873885A3 (fr)
YU (1) YU40829B (fr)
ZA (1) ZA782919B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088945A (fr) * 1976-10-18 1980-11-04 Pfizer Limited Derives de l'hydantoine utilises comme agents therapeutiques
US4181728A (en) * 1978-11-16 1980-01-01 Pfizer Inc. Spiro-polycyclicimidazolidinedione derivatives
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
US4286098A (en) * 1980-03-28 1981-08-25 Pfizer Inc. Process for the preparation of chiral hydantoins
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
US4419521A (en) * 1981-11-12 1983-12-06 Pfizer Inc. 6-Halo-4-chromanamines useful as intermediates to make chiral hydantoins
JPS58124788A (ja) * 1982-01-20 1983-07-25 Eisai Co Ltd 光学活性ヒダントイン誘導体，その製造方法ならびにそれを含有する治療用薬剤
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4464385A (en) * 1982-04-15 1984-08-07 Alcon Laboratories, Inc. Treatment of diabetic complications with hydantoins
US4540700A (en) * 1982-04-15 1985-09-10 Alcon Laboratories, Inc. Treatment of diabetic complications with certain spiro-imidazolidine-diones
US4528387A (en) * 1982-11-10 1985-07-09 Pfizer Inc. Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid
US4431828A (en) * 1982-11-10 1984-02-14 Pfizer Inc. Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US5153211A (en) * 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
EP0159143B1 (fr) * 1984-03-23 1987-12-16 Pfizer Inc. Spiro-indènes et spiro-dihydro-1,2-naphtalènes pour le traitement de complications diabétiques
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
JPH06772B2 (ja) * 1984-07-09 1994-01-05 鐘淵化学工業株式会社 ３―（４―フルオロフエノキシ）プロピオニトリルを用いる６―フルオロ―４―クロマノンの製造法
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
US4656169A (en) * 1984-08-14 1987-04-07 Pfizer Inc. Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions
DE3565105D1 (en) * 1984-08-20 1988-10-27 Pfizer Process for the production as asymmetric hydantoins
US4620019A (en) * 1984-08-23 1986-10-28 Pfizer Inc. S-6-fluoro-4-aminochroman-4-carboxylic acid derivatives useful as intermediates for sorbinil
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4551542A (en) * 1984-09-26 1985-11-05 Pfizer Inc. Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
WO1986007353A1 (fr) 1985-06-14 1986-12-18 Pfizer Inc. Produit intermediaire utilise dans la producton d'hydantoines asymetriques
JPS627654U (fr) * 1985-06-26 1987-01-17
HU206618B (en) * 1986-01-17 1992-12-28 Pfizer Process for producing hydroxyacetic acid derivatives for treating complications of diabetes and pharmaceutical compositions containing them
JPS6357588A (ja) * 1986-08-28 1988-03-12 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
EP0306525A4 (en) * 1987-03-20 1991-04-24 Alcon Laboratories Inc Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
US5006657A (en) * 1988-07-27 1991-04-09 Pfizer Inc. Intermediates in a resolution process for racemic spiro hydantoins
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
WO1992000071A1 (fr) * 1989-02-10 1992-01-09 Washington Research Foundation Agents immunoregulateurs
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5206367A (en) * 1992-02-18 1993-04-27 Pfizer Inc. Preparation of optically active spiro-hydantoins
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
US5521208A (en) * 1993-07-29 1996-05-28 Alcon Laboratories, Inc. Compositions and methods for the treatment of the metabolically impaired and for improved compliance
HUP0000838A3 (en) * 1997-04-15 2001-04-28 Csir Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
PL365378A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8158667B2 (en) 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EP2654749B1 (fr) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Méthodes de traitement de copd
UA118035C2 (uk) * 2013-10-07 2018-11-12 Сінгента Партісіпейшнс Аг Гербіцидні сполуки
WO2019165195A1 (fr) 2018-02-22 2019-08-29 Srivastava Satish Polythérapie destinée au traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
CA1088945A (fr) * 1976-10-18 1980-11-04 Pfizer Limited Derives de l'hydantoine utilises comme agents therapeutiques

Also Published As

Publication number Publication date
AR219531A1 (es) 1980-08-29
FI62838C (fi) 1983-03-10
HU177718B (en) 1981-12-28
IE47273B1 (en) 1984-02-08
FR2392024B1 (fr) 1981-07-24
IT7823672A0 (it) 1978-05-22
PL206826A1 (pl) 1979-04-23
IN147854B (fr) 1980-07-19
IL54754A0 (en) 1978-07-31
NZ187334A (en) 1984-04-27
DD137107A5 (de) 1979-08-15
LU79685A1 (fr) 1979-12-06
GR68694B (fr) 1982-02-01
JPS6035350B2 (ja) 1985-08-14
DK226778A (da) 1978-11-24
SU873885A3 (ru) 1981-10-15
ZA782919B (en) 1979-06-27
ATA365378A (de) 1979-11-15
GB1572688A (en) 1980-07-30
PT68071A (en) 1978-06-01
KE3168A (en) 1981-11-06
DE2858042C2 (de) 1983-11-24
CA1088073A (fr) 1980-10-21
IL54754A (en) 1982-04-30
NO150206B (no) 1984-05-28
IT1096306B (it) 1985-08-26
ES470070A1 (es) 1979-01-01
MY8200156A (en) 1982-12-31
US4130714A (en) 1978-12-19
FI62838B (fi) 1982-11-30
AT357170B (de) 1980-06-25
DE2821966A1 (de) 1978-11-30
IE781015L (en) 1978-11-23
JPS53144575A (en) 1978-12-15
SE7803626L (sv) 1978-11-24
CS200550B2 (en) 1980-09-15
BE867248A (fr) 1978-11-20
YU40829B (en) 1986-06-30
FR2392024A1 (fr) 1978-12-22
DK147941B (da) 1985-01-14
FI781613A (fi) 1978-11-24
HK53981A (en) 1981-11-13
DK147941C (da) 1985-08-26
SE437375B (sv) 1985-02-25
PL110460B1 (en) 1980-07-31
YU116978A (en) 1983-02-28
NL7804158A (nl) 1978-11-27
DE2821966C2 (de) 1983-06-01
NO781769L (no) 1978-11-24
AU499518B1 (en) 1979-04-26
CH631455A5 (fr) 1982-08-13
PT68071B (en) 1979-10-26
PH13828A (en) 1980-10-07
NO150206C (no) 1984-09-05

Similar Documents

Publication Publication Date Title
EG13691A (en) Process for preparing hydration therapeutic agents
GB2004493B (en) Process for preparing aluminus
JPS53147036A (en) Process for preparing fluorobenzole
PT68834A (en) Process for preparing therapeutic agents
GB2011899A (en) Process for preparing vincadifformine
HU179428B (en) Process for preparing 1-acyl-2-cyano-aziridines
JPS53124206A (en) Process for preparing ethylfneglycol
HU179663B (en) Process for preparing d-alpha-aminoacids
HU179803B (en) Process for preparing glucopyranose-nitroso-carbamides
JPS53119837A (en) Process for preparing nitrosobenzole
JPS53130612A (en) Process for preparing ethlenfglycoldimethylether
JPS53105426A (en) Process for preparing acylcyanate
YU279178A (en) Process for preparing 3-iodo-and 3-bromo-rifamycin s
JPS53124212A (en) Process for preparing 33methyll22butenee11ol
DE2860177D1 (en) Process for preparing acetylaminobenzenes
GB2012756B (en) Process for preparing 5-arylhydantoins
DE2860421D1 (en) Process for preparing 1-amino-2-sulfo-4-bromanthraquinone
JPS53121750A (en) Process for preparing naphtylaminehydroxysulfonate
DE2860171D1 (en) Process for preparing 1-amino-2-sulfo-4-bromo-anthraquinone
JPS53105423A (en) Process for preparing alphaaketocarboxylate
PT71399A (en) Process for preparing pyridylaminotriazole therapeutic agents
JPS53112813A (en) Process for preparing diinnpropylacetonitrile
IL54355A (en) Process for preparing 2-hydroxy-benzothiazole
IL55072A0 (en) Process for preparing butyl-p-benzoylbenzoates
JPS53112805A (en) Process for preparing diinnpropylacetamide